Investors

Commonwealth Capital

At Commonwealth Capital, we focus on early-stage companies in the Software, Communications and Instrumentation sectors. Our team of experienced venture capital partners works closely with entrepreneurial management teams to help them build outstanding growth companies and deliver superior returns to investors.

Flagship Ventures

Flagship Ventures is an early-stage venture capital firm focused on creating, financing, and building innovative companies in the Life Science and Technology sectors. Headquartered in Cambridge, MA, Flagship Ventures was founded in 1999 and manages $700 million in capital. Prior to its founding, Flagship's principals were involved as founders or investors in over 100 firms including: Adolor, AltaVista, Anesta, Antigenics, Aspect Medical, Astral Point, Celera Genomics, ChemGenics Pharmaceuticals, Color Kinetics, Chantry Networks, Cytyc, DataSage, Exact Sciences, IDEXX, PerSeptive Biosystems, Somatogen, Telecorp PCS and TripAdvisor.

Rock Maple Ventures

Rock Maple Ventures targets leading opportunities within the technology and healthcare markets where the operating executives, including our Industry Partners, have a track record of success and the expertise to add value. We pursue companies with revenue traction and reference customers that can benefit from additional equity capital to accelerates growth, develop new products or acquire other companies. Rock Maple Ventures has offices in Boston and New York and invests nationwide wherever promising technology and healthcare companies emerge.

Rock Maple Ventures invests in companies that are developing innovative technologies to create new products and services, solve real problems, and expand or redistribute the value chain in dynamic industries. With $80 million in capital and over 30 years of real-world executive, investment and entrepreneurial experience, Rock Maple Ventures is an active, value-added investor.

LSP BioVentures

LSP BioVentures is a US based life science fund which was launched in June 2006. The fund invests primarily in early to mid-stage product and platform companies covering a variety of sectors including: agriculture, food & nutrition, health & wellness, Cleantech and platform technologies. LSP BioVentures is the fourth fund under the LSP Group.

LSP Group provides private equity financing to early- to mid-stage life-science companies in Europe and the US. With over $500 million under management and offices in Amsterdam, Munich and Boston, LSP has over two decades of experience as specialist life-science investors.